Candel Therapeutics, Inc. filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-09-10. Between them they name 1 person. Each change below is quoted from the filing and linked to it.
Every change, newest first
Appointed: Martine Zimmermann, Director, effective 2026-09-08
On September 6, 2026, the Board of Directors (the "Board") of Candel Therapeutics, Inc. (the "Company") increased the size of the Board from ten (10) to eleven (11) directors and unanimously appointed Martine Zimmermann, Pharm.D, to fill the newly created vacancy on the Board, effective September 8, 2026.
Find people with the same kind of experience as the Director at Candel Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Candel Therapeutics, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Candel Therapeutics, Inc. is in the news or changes leadership.
Get an alert when Candel Therapeutics, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Candel Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.